{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:57:53Z","timestamp":1778039873303,"version":"3.51.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03876-3","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:14:42Z","timestamp":1769494482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-6239","authenticated-orcid":false,"given":"Subrata","family":"Pramanik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-9909","authenticated-orcid":false,"given":"Manisha","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-8712","authenticated-orcid":false,"given":"Pok-Son","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5061-6936","authenticated-orcid":false,"given":"Arne","family":"Kutzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3257-993X","authenticated-orcid":false,"given":"Arulmani","family":"Manavalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9117-4887","authenticated-orcid":false,"given":"Gopal","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-6993","authenticated-orcid":false,"given":"Klaus","family":"Heese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"3876_CR1","unstructured":"Ferlay JEM, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.fr\/today. 2020: accessed 02\/02\/2021."},{"key":"3876_CR2","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"CGD de Martel","year":"2020","unstructured":"de Martel CGD, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180\u20131190.","journal-title":"Lancet Glob Health"},{"key":"3876_CR3","unstructured":"WHO. (2023) Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. https:\/\/www.who.int\/publications\/i\/item\/9789240105997"},{"key":"3876_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74:229\u201363.","journal-title":"Cancer J Clin"},{"key":"3876_CR5","first-page":"34","volume":"39","author":"JF Rossi","year":"2019","unstructured":"Rossi JF, C\u00e9ballos P, Lu ZY. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond). 2019;39:34.","journal-title":"Cancer Commun (Lond)"},{"key":"3876_CR6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"3876_CR7","unstructured":"National Cancer Institute. (2022) CAR T Cells: Engineering Patients\u2019 Immune Cells to Treat Their Cancers. https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells"},{"key":"3876_CR8","doi-asserted-by":"crossref","unstructured":"Ivica NA, Young CM. Tracking the CAR-T revolution: analysis of clinical trials of CAR-T and TCR-T therapies for the treatment of cancer (1997\u20132020). Healthcare (Basel). 2021;9.","DOI":"10.20944\/preprints202107.0198.v1"},{"key":"3876_CR9","doi-asserted-by":"crossref","first-page":"632937","DOI":"10.3389\/fimmu.2021.632937","volume":"12","author":"M Jasi\u0144ski","year":"2021","unstructured":"Jasi\u0144ski M, Basak GW, Jedrzejczak WW. Perspectives for the use of CAR-T cells for the treatment of multiple myeloma. Front Immunol. 2021;12:632937.","journal-title":"Front Immunol"},{"key":"3876_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"3876_CR11","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, et al. CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 2019;42:2183\u201395.","journal-title":"Oncol Rep"},{"key":"3876_CR12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","volume":"114","author":"A Biederst\u00e4dt","year":"2021","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021;114:554\u201371.","journal-title":"Int J Hematol"},{"key":"3876_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"3876_CR14","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"3876_CR15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26:1569\u201375.","journal-title":"Nat Med"},{"key":"3876_CR16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11899-019-00537-5","volume":"14","author":"Z Walsh","year":"2019","unstructured":"Walsh Z, Ross S, Fry TJ. Multi-Specific CAR targeting to prevent antigen escape. Curr Hematol Malig Rep. 2019;14:451\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"3876_CR17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-20-0470","volume":"9","author":"AJ Johnson","year":"2021","unstructured":"Johnson AJ, et al. Rationally designed Transgene-Encoded Cell-Surface polypeptide Tag for multiplexed programming of CAR T-cell synthetic outputs. Cancer Immunol Res. 2021;9:1047\u201360.","journal-title":"Cancer Immunol Res"},{"key":"3876_CR18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419\u201331.","journal-title":"Nat Med"},{"key":"3876_CR19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/j.1582-4934.2010.01134.x","volume":"15","author":"M Mishra","year":"2011","unstructured":"Mishra M, Akatsu H, Heese K. The novel protein MANI modulates neurogenesis and neurite-cone growth. J Cell Mol Med. 2011;15:1713\u201325.","journal-title":"J Cell Mol Med"},{"key":"3876_CR20","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.febslet.2012.06.043","volume":"586","author":"M Mishra","year":"2012","unstructured":"Mishra M, Lee S, Lin MK, Yamashita T, Heese K. Characterizing the neurite outgrowth inhibitory effect of Mani. FEBS Lett. 2012;586:3018\u201323.","journal-title":"FEBS Lett"},{"key":"3876_CR21","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-18-0619","volume":"78","author":"MDM Maldonado","year":"2018","unstructured":"Maldonado MDM, Dharmawardhane S. Targeting Rac and Cdc42 GTPases in cancer. Cancer Res. 2018;78:3101\u201311.","journal-title":"Cancer Res"},{"key":"3876_CR22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, et al. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:145.","journal-title":"Mol Cancer"},{"key":"3876_CR23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12935-021-01860-9","volume":"21","author":"GE Kazemi-Sefat","year":"2021","unstructured":"Kazemi-Sefat GE, et al. The importance of CDC27 in cancer: molecular pathology and clinical aspects. Cancer Cell Int. 2021;21:160.","journal-title":"Cancer Cell Int"},{"key":"3876_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41389-022-00392-9","volume":"11","author":"H Liu","year":"2022","unstructured":"Liu H, et al. TCRP1 activated by mutant p53 promotes NSCLC proliferation via inhibiting FOXO3a. Oncogenesis. 2022;11:19.","journal-title":"Oncogenesis"},{"key":"3876_CR25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13046-017-0582-5","volume":"36","author":"Y Gu","year":"2017","unstructured":"Gu Y, et al. Epigenetic Silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1). J Exp Clin Cancer Res. 2017;36:114.","journal-title":"J Exp Clin Cancer Res"},{"key":"3876_CR26","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1\u20131.","journal-title":"Sci Signal"},{"key":"3876_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-018-03029-3","volume":"141","author":"CS Rahane","year":"2019","unstructured":"Rahane CS, Kutzner A, Heese K. A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J Neurooncol. 2019;141:57\u201370.","journal-title":"J Neurooncol"},{"key":"3876_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2018.10.005","volume":"230","author":"CS Rahane","year":"2019","unstructured":"Rahane CS, Kutzner A, Heese K. Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. Cancer Genet. 2019;230:1\u201312.","journal-title":"Cancer Genet"},{"key":"3876_CR29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.2015.288","volume":"113","author":"M Mullooly","year":"2015","unstructured":"Mullooly M, et al. ADAM10: a new player in breast cancer progression? Br J Cancer. 2015;113:945\u201351.","journal-title":"Br J Cancer"},{"key":"3876_CR30","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1038\/s41467-022-35043-5","volume":"13","author":"M Ale\u010dkovi\u0107","year":"2022","unstructured":"Ale\u010dkovi\u0107 M, et al. Breast cancer prevention by short-term Inhibition of TGF\u03b2 signaling. Nat Commun. 2022;13:7558.","journal-title":"Nat Commun"},{"key":"3876_CR31","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1002\/cam4.3345","volume":"9","author":"SC Larsson","year":"2020","unstructured":"Larsson SC, et al. Insulin-like growth factor-1 and site-specific cancers: A Mendelian randomization study. Cancer Med. 2020;9:6836\u201342.","journal-title":"Cancer Med"},{"key":"3876_CR32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fcvm.2020.00034","volume":"7","author":"W Parichatikanond","year":"2020","unstructured":"Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H. Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-\u03b2 signaling. Front Cardiovasc Med. 2020;7:34.","journal-title":"Front Cardiovasc Med"},{"key":"3876_CR33","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"3876_CR34","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","volume":"29","author":"R Hassan","year":"2023","unstructured":"Hassan R, et al. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results. Nat Med. 2023;29:2099\u2013109.","journal-title":"Nat Med"},{"key":"3876_CR35","doi-asserted-by":"crossref","first-page":"627549","DOI":"10.3389\/fonc.2021.627549","volume":"11","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Khoshtinat Nikkhoi S. Strategies for dodging the Obstacles in CAR T cell therapy. Front Oncol. 2021;11:627549.","journal-title":"Front Oncol"},{"key":"3876_CR36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12:81.","journal-title":"Stem Cell Res Ther"},{"key":"3876_CR37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","volume":"12","author":"S Karkampouna","year":"2021","unstructured":"Karkampouna S, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun. 2021;12:1117.","journal-title":"Nat Commun"},{"key":"3876_CR38","doi-asserted-by":"crossref","unstructured":"Huang L et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight. 2020;5:e135544.","DOI":"10.1172\/jci.insight.135544"},{"key":"3876_CR39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Experimental Clin Cancer Res. 2021;40:367.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3876_CR40","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11:2283.","journal-title":"Nat Commun"},{"key":"3876_CR41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/25785826.2020.1796063","volume":"44","author":"N Hosen","year":"2021","unstructured":"Hosen N. CAR T cell therapy. Immunol Med. 2021;44:69\u201373.","journal-title":"Immunol Med"},{"key":"3876_CR42","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"3876_CR43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"3876_CR44","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"3876_CR45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 Blockade. Nat Med. 2018;24:731\u20138.","journal-title":"Nat Med"},{"key":"3876_CR46","doi-asserted-by":"crossref","first-page":"1272291","DOI":"10.3389\/fmed.2023.1272291","volume":"10","author":"F Del Duca","year":"2023","unstructured":"Del Duca F, et al. Blood-brain barrier breakdown, central nervous system cell damage, and infiltrated T cells as major adverse effects in CAR-T-related deaths: a literature review. Front Med. (Lausanne). 2023;10:1272291.","journal-title":"Front Med (Lausanne)"},{"key":"3876_CR47","doi-asserted-by":"crossref","unstructured":"Pinto SN, Krenciute G. The mechanisms of altered Blood-Brain barrier permeability in CD19 CAR T-Cell recipients. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25010644"},{"key":"3876_CR48","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3389\/fimmu.2018.03062","volume":"9","author":"P Chuntova","year":"2018","unstructured":"Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H. Genetically engineered T-Cells for malignant glioma: overcoming the barriers to effective immunotherapy. Front Immunol. 2018;9:3062.","journal-title":"Front Immunol"},{"key":"3876_CR49","doi-asserted-by":"crossref","first-page":"805657","DOI":"10.3389\/fimmu.2022.805657","volume":"13","author":"JA Mapunda","year":"2022","unstructured":"Mapunda JA, Tibar H, Regragui W, Engelhardt B. How does the immune system enter the brain? Front Immunol. 2022;13:805657.","journal-title":"Front Immunol"},{"key":"3876_CR50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","volume":"33","author":"B Engelhardt","year":"2012","unstructured":"Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012;33:579\u201389.","journal-title":"Trends Immunol"},{"key":"3876_CR51","doi-asserted-by":"crossref","first-page":"188701","DOI":"10.1016\/j.bbcan.2022.188701","volume":"1877","author":"P Akbari","year":"2022","unstructured":"Akbari P, et al. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. Biochim Biophys Acta Rev Cancer. 2022;1877:188701.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3876_CR52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunp\u00e4\u00e4","year":"2019","unstructured":"Harjunp\u00e4\u00e4 H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078.","journal-title":"Front Immunol"},{"key":"3876_CR53","doi-asserted-by":"crossref","first-page":"113501","DOI":"10.1016\/j.celrep.2023.113501","volume":"42","author":"J Goretzko","year":"2023","unstructured":"Goretzko J, et al. P-selectin-dependent leukocyte adhesion is governed by endolysosomal two-pore channel 2. Cell Rep. 2023;42:113501.","journal-title":"Cell Rep"},{"key":"3876_CR54","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.bcmd.2020.102424","volume":"83","author":"Y Man","year":"2020","unstructured":"Man Y, et al. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. Blood Cells Mol Dis. 2020;83:102424.","journal-title":"Blood Cells Mol Dis"},{"key":"3876_CR55","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/eji.201545632","volume":"45","author":"G Martin-Blondel","year":"2015","unstructured":"Martin-Blondel G, et al. Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the \u03b14\u03b21-integrin. Eur J Immunol. 2015;45:3302\u201312.","journal-title":"Eur J Immunol"},{"key":"3876_CR56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI12440","volume":"108","author":"P Vajkoczy","year":"2001","unstructured":"Vajkoczy P, Laschinger M, Engelhardt B. Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest. 2001;108:557\u201365.","journal-title":"J Clin Invest"},{"key":"3876_CR57","doi-asserted-by":"crossref","first-page":"830292","DOI":"10.3389\/fimmu.2022.830292","volume":"13","author":"AE Andrea","year":"2022","unstructured":"Andrea AE, et al. Advances in CAR-T cell genetic engineering strategies to overcome hurdles in solid tumors treatment. Front Immunol. 2022;13:830292.","journal-title":"Front Immunol"},{"key":"3876_CR58","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for Finding, Infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"key":"3876_CR59","doi-asserted-by":"crossref","first-page":"115272","DOI":"10.1016\/j.biopha.2023.115272","volume":"165","author":"X Zheng","year":"2023","unstructured":"Zheng X, Ren B, Gao Y. Tight junction proteins related to blood-brain barrier and their regulatory signaling pathways in ischemic stroke. Biomed Pharmacother. 2023;165:115272.","journal-title":"Biomed Pharmacother"},{"key":"3876_CR60","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1152\/physrev.00019.2012","volume":"93","author":"D G\u00fcnzel","year":"2013","unstructured":"G\u00fcnzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93:525\u201369.","journal-title":"Physiol Rev"},{"key":"3876_CR61","doi-asserted-by":"crossref","first-page":"100543","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022;3:100543.","journal-title":"Cell Rep Med"},{"key":"3876_CR62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for Next-Generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"3876_CR63","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so Far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3876_CR64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3876_CR65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.","journal-title":"Front Pharmacol"},{"key":"3876_CR66","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.","journal-title":"Front Pharmacol"},{"key":"3876_CR67","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1073\/pnas.96.15.8699","volume":"96","author":"C Beltinger","year":"1999","unstructured":"Beltinger C, et al. Herpes simplex virus thymidine kinase\/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci U S A. 1999;96:8699\u2013704.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3876_CR68","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"3876_CR69","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M\u2009+\u2009diffuse midline gliomas. Nature. 2025;637:708\u201315.","journal-title":"Nature"},{"key":"3876_CR70","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00277-023-05227-0","volume":"102","author":"X Xiong","year":"2023","unstructured":"Xiong X, et al. Functional validation of the RQR8 suicide \/Marker gene in CD19 CAR-T cells and CLL1CAR-T cells. Ann Hematol. 2023;102:1523\u201335.","journal-title":"Ann Hematol"},{"key":"3876_CR71","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","volume":"4","author":"R Sakemura","year":"2016","unstructured":"Sakemura R, et al. A Tet-On inducible system for controlling CD19-Chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4:658\u201368.","journal-title":"Cancer Immunol Res"},{"key":"3876_CR72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","volume":"6","author":"M Mamonkin","year":"2018","unstructured":"Mamonkin M, et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6:47\u201358.","journal-title":"Cancer Immunol Res"},{"key":"3876_CR73","doi-asserted-by":"crossref","first-page":"e202109550","DOI":"10.1002\/anie.202109550","volume":"61","author":"W Cao","year":"2022","unstructured":"Cao W, et al. A reversible chemogenetic switch for chimeric antigen receptor T\u2005Cells. Angew Chem Int Ed Engl. 2022;61:e202109550.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3876_CR74","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, et al. Ionizable lipid Nanoparticle-Mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20:1578\u201389.","journal-title":"Nano Lett"},{"key":"3876_CR75","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn RC, et al. High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia. 2016;30:1355\u201364.","journal-title":"Leukemia"},{"key":"3876_CR76","first-page":"185","volume":"12","author":"L Raes","year":"2020","unstructured":"Raes L, et al. Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation. Nanomicro Lett. 2020;12:185.","journal-title":"Nanomicro Lett"},{"key":"3876_CR77","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, et al. Treating Relapsed \/ Refractory (RR) AML with biodegradable Anti-CD123 CAR modified T cells. Blood. 2017;130:1359\u20131359.","journal-title":"Blood"},{"key":"3876_CR78","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41467-019-11893-4","volume":"10","author":"F Zou","year":"2019","unstructured":"Zou F, et al. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nat Commun. 2019;10:4109.","journal-title":"Nat Commun"},{"key":"3876_CR79","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173\u201385.","journal-title":"Nat Rev Immunol"},{"key":"3876_CR80","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fimmu.2015.00310","volume":"6","author":"SA Fuertes Marraco","year":"2015","unstructured":"Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310.","journal-title":"Front Immunol"},{"key":"3876_CR81","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the Immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11:3887\u201395.","journal-title":"Embo J"},{"key":"3876_CR82","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 Blockade. Science. 1996;271:1734\u20136.","journal-title":"Science"},{"key":"3876_CR83","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, et al. Counteracting CAR T cell dysfunction. Oncogene. 2021;40:421\u201335.","journal-title":"Oncogene"},{"key":"3876_CR84","doi-asserted-by":"crossref","first-page":"1034257","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.","journal-title":"Front Cell Dev Biol"},{"key":"3876_CR85","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cell.2018.11.006","volume":"175","author":"J Wolchok","year":"2018","unstructured":"Wolchok J. Putting the Immunologic brakes on cancer. Cell. 2018;175:1452\u20134.","journal-title":"Cell"},{"key":"3876_CR86","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint Blockade resist tumor-mediated Inhibition. J Clin Invest. 2016;126:3130\u201344.","journal-title":"J Clin Invest"},{"key":"3876_CR87","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1002\/cti2.1041","volume":"7","author":"MJ Smyth","year":"2018","unstructured":"Smyth MJ, Teng MW. 2018 nobel prize in physiology or medicine. Clin Transl Immunol. 2018;7:e1041.","journal-title":"Clin Transl Immunol"},{"key":"3876_CR88","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","volume":"562","author":"H Ledford","year":"2018","unstructured":"Ledford H, Else H, Warren M. Cancer immunologists scoop medicine nobel prize. Nature. 2018;562:20\u20131.","journal-title":"Nature"},{"key":"3876_CR89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint Blockade for the treatment of solid tumors. Cancer Cell. 2019;36:471\u201382.","journal-title":"Cancer Cell"},{"key":"3876_CR90","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023;14:466.","journal-title":"Cell Death Dis"},{"key":"3876_CR91","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044\u201360.","journal-title":"Curr Oncol"},{"key":"3876_CR92","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint Blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"3876_CR93","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27:195\u2013201.","journal-title":"Trends Immunol"},{"key":"3876_CR94","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"3876_CR95","doi-asserted-by":"crossref","first-page":"1325462","DOI":"10.3389\/fimmu.2023.1325462","volume":"14","author":"T Kurosaki","year":"2023","unstructured":"Kurosaki T, et al. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 Blockade in patients with advanced cancers: a multicenter retrospective study. Front Immunol. 2023;14:1325462.","journal-title":"Front Immunol"},{"key":"3876_CR96","doi-asserted-by":"crossref","first-page":"1349081","DOI":"10.3389\/fphar.2023.1349081","volume":"14","author":"J Su","year":"2023","unstructured":"Su J, et al. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Front Pharmacol. 2023;14:1349081.","journal-title":"Front Pharmacol"},{"key":"3876_CR97","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","volume":"10","author":"K Thudium","year":"2022","unstructured":"Thudium K, et al. Preclinical characterization of Relatlimab, a human LAG-3-Blocking Antibody, alone or in combination with nivolumab. Cancer Immunol Res. 2022;10:1175\u201389.","journal-title":"Cancer Immunol Res"},{"key":"3876_CR98","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660\u20139.","journal-title":"Cell Res"},{"key":"3876_CR99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng L, et al. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Cell Death Dis. 2024;15:3.","journal-title":"Cell Death Dis"},{"key":"3876_CR100","doi-asserted-by":"crossref","unstructured":"Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbanzadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC, Silvestris N, Baradaran B. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? Int J Mol Sci. 2020 Nov 5;21(21):8305.","DOI":"10.3390\/ijms21218305"},{"key":"3876_CR101","doi-asserted-by":"crossref","first-page":"687822","DOI":"10.3389\/fimmu.2021.687822","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Z, Ren Z, Tang F, Li Y. Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors. Front Immunol. 2021;12:687822.","journal-title":"Front Immunol"},{"key":"3876_CR102","doi-asserted-by":"crossref","first-page":"934343","DOI":"10.3389\/fimmu.2022.934343","volume":"13","author":"T Riet","year":"2022","unstructured":"Riet T, Chmielewski M. Regulatory CAR-T cells in autoimmune diseases: progress and current challenges. Front Immunol. 2022;13:934343.","journal-title":"Front Immunol"},{"key":"3876_CR103","doi-asserted-by":"crossref","first-page":"616949","DOI":"10.3389\/fimmu.2020.616949","volume":"11","author":"L Rocamora-Reverte","year":"2020","unstructured":"Rocamora-Reverte L, Melzer FL, W\u00fcrzner R, Weinberger B. The complex role of regulatory T cells in immunity and aging. Front Immunol. 2020;11:616949.","journal-title":"Front Immunol"},{"key":"3876_CR104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3876_CR105","doi-asserted-by":"crossref","first-page":"1267762","DOI":"10.3389\/fmolb.2023.1267762","volume":"10","author":"CJ Requejo Cier","year":"2023","unstructured":"Requejo Cier CJ, Valentini N, Lamarche C. Unlocking the potential of tregs: innovations in CAR technology. Front Mol Biosci. 2023;10:1267762.","journal-title":"Front Mol Biosci"},{"key":"3876_CR106","doi-asserted-by":"crossref","unstructured":"Aksoy P, Aksoy BA, Czech E, Hammerbacher J. Viable and efficient electroporation-based genetic manipulation of unstimulated human T cells. BioRxiv. 2019:466243.","DOI":"10.1101\/466243"},{"key":"3876_CR107","unstructured":"Aksoy BA, Aksoy P, Gottschalk E, Hammerbacher J. Flow-cytometry-based in vitro assay for assessing T-cell-mediated cytotoxicity against a target cell line (24-well plate, pmel-1 or OT-I T cells, MC38 cell line). protocols.io. 2019."},{"key":"3876_CR108","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","volume":"16","author":"S Kiesgen","year":"2021","unstructured":"Kiesgen S, Messinger JC, Chintala NK, Tano Z, Adusumilli PS. Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nat Protoc. 2021;16:1331\u201342.","journal-title":"Nat Protoc"},{"key":"3876_CR109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2005.10.018","volume":"309","author":"J Zhu","year":"2006","unstructured":"Zhu J, Wang X, Xu X, Abassi YA. Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods. 2006;309:25\u201333.","journal-title":"J Immunol Methods"},{"key":"3876_CR110","doi-asserted-by":"crossref","unstructured":"Lisby AN, Carlson RD, Baybutt TR, Weindorfer M, Snook AE. In: Galluzzi L, editor. Chap. 5 - Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis; in methods in cell Biology, Spada. Academic; 2022. pp. 81\u201398.","DOI":"10.1016\/bs.mcb.2021.08.002"},{"key":"3876_CR111","doi-asserted-by":"crossref","unstructured":"Hamidi H, Lilja J, Ivaska J. Using xCELLigence RTCA Instrument to Measure Cell Adhesion. Bio Protoc. 2017 Dec 20;7(24):e2646.","DOI":"10.21769\/BioProtoc.2646"},{"key":"3876_CR112","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-1-0716-3858-3_12","volume":"2806","author":"LK Philp","year":"2024","unstructured":"Philp LK. Patient-Derived xenograft models for translational prostate cancer research and drug development. Methods Mol Biol. 2024;2806:153\u201385.","journal-title":"Methods Mol Biol"},{"key":"3876_CR113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8:160.","journal-title":"Signal Transduct Target Ther"},{"key":"3876_CR114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41571-022-00682-6","volume":"19","author":"ER Zanella","year":"2022","unstructured":"Zanella ER, Grassi E, Trusolino L. Towards precision oncology with patient-derived xenografts. Nat Rev Clin Oncol. 2022;19:719\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"3876_CR115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrurol.2017.19","volume":"14","author":"T Inoue","year":"2017","unstructured":"Inoue T, Terada N, Kobayashi T, Ogawa O. Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol. 2017;14:267\u201383.","journal-title":"Nat Rev Urol"},{"key":"3876_CR116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","volume":"27","author":"BB Duncan","year":"2022","unstructured":"Duncan BB, Dunbar CE, Ishii K. Applying a clinical lens to animal models of CAR-T cell therapies. Mol Ther Methods Clin Dev. 2022;27:17\u201331.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3876_CR117","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-023-40852-3","volume":"14","author":"LH Porter","year":"2023","unstructured":"Porter LH, et al. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models. Nat Commun. 2023;14:5346.","journal-title":"Nat Commun"},{"key":"3876_CR118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-020-00405-z","volume":"11","author":"AK Mishra","year":"2021","unstructured":"Mishra AK, Kemler I, Dingli D. Preclinical development of CD126 CAR-T cells with broad antitumor activity. Blood Cancer J. 2021;11:3.","journal-title":"Blood Cancer J"},{"key":"3876_CR119","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-021-07934-1","volume":"21","author":"Z Ying","year":"2021","unstructured":"Ying Z, et al. Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. BMC Cancer. 2021;21:198.","journal-title":"BMC Cancer"},{"key":"3876_CR120","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129:2395\u2013407.","journal-title":"Blood"},{"key":"3876_CR121","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3389\/fimmu.2016.00214","volume":"7","author":"Z Jiang","year":"2016","unstructured":"Jiang Z, et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in Patient-Derived xenografts of hepatocellular carcinoma. Front Immunol. 2016;7:690.","journal-title":"Front Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03876-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03876-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03876-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:57:21Z","timestamp":1771423041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03876-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3876"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03876-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}